InMode Ltd. (NASDAQ:INMD) Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. trimmed its holdings in shares of InMode Ltd. (NASDAQ:INMD - Free Report) by 10.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 303,328 shares of the healthcare company's stock after selling 36,800 shares during the period. Russell Investments Group Ltd. owned 0.44% of InMode worth $5,066,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in INMD. State Street Corp grew its position in shares of InMode by 3.7% in the 3rd quarter. State Street Corp now owns 2,044,640 shares of the healthcare company's stock valued at $34,657,000 after buying an additional 73,183 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of InMode by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,101,951 shares of the healthcare company's stock valued at $18,678,000 after purchasing an additional 6,282 shares during the last quarter. JPMorgan Chase & Co. grew its stake in InMode by 4.4% during the 4th quarter. JPMorgan Chase & Co. now owns 1,084,241 shares of the healthcare company's stock worth $18,107,000 after buying an additional 45,638 shares during the last quarter. River Road Asset Management LLC acquired a new position in InMode during the fourth quarter worth approximately $8,572,000. Finally, Yelin Lapidot Holdings Management Ltd. lifted its stake in InMode by 0.6% in the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 308,852 shares of the healthcare company's stock valued at $5,158,000 after buying an additional 1,950 shares during the last quarter. 68.04% of the stock is owned by institutional investors and hedge funds.

InMode Stock Performance

NASDAQ:INMD traded up $0.01 during mid-day trading on Friday, reaching $14.92. The stock had a trading volume of 870,722 shares, compared to its average volume of 1,179,342. The business has a 50 day simple moving average of $17.76 and a 200 day simple moving average of $17.61. InMode Ltd. has a twelve month low of $13.68 and a twelve month high of $19.85. The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of 6.35 and a beta of 1.96.

Analyst Ratings Changes

Several research firms recently commented on INMD. Barclays upped their price target on shares of InMode from $26.00 to $29.00 and gave the company an "overweight" rating in a research report on Wednesday, February 5th. Jefferies Financial Group dropped their price target on InMode from $16.00 to $15.00 and set a "hold" rating on the stock in a research report on Monday. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of InMode in a research report on Wednesday, April 9th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, InMode has a consensus rating of "Hold" and a consensus target price of $21.25.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.